Home
Market Capitalization of Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd
NSE: ASTRAZEN
Market Cap
Key Highlights
- The Market Cap of Astrazeneca Pharma India Ltd is ₹ 22344 crore as of 02 Sep 25 .
- The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 9070 as of 03 Sep 12:35 .
- The Dividend Payouts of Astrazeneca Pharma India Ltd changed from ₹ 2 on Aug 20, 2020 to ₹ 32 on Jul 18, 2025 . This represents a CAGR of 58.74% over 6 years.

Astrazeneca Pharma India Ltd
NSE: ASTRAZEN
Share Price
Market Price of Astrazeneca Pharma India Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
02 Sep 2025 | 8937.85 |
01 Sep 2025 | 8751.75 |
29 Aug 2025 | 8469.45 |
28 Aug 2025 | 8322.7 |
26 Aug 2025 | 8014.9 |
25 Aug 2025 | 8297.1 |
22 Aug 2025 | 8431.65 |
21 Aug 2025 | 8397.35 |
20 Aug 2025 | 8450.65 |
19 Aug 2025 | 8472.9 |
SWOT Analysis Of Astrazeneca Pharma India Ltd
BlinkX Score for Astrazeneca Pharma India Ltd
Asset Value vs Market Value of Astrazeneca Pharma India Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of Market Cap
Key Valuation Metric of Astrazeneca Pharma India Ltd
Historical P/E Ratio of Astrazeneca Pharma India Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Astrazeneca Pharma India Ltd
Historical Revenue of Astrazeneca Pharma India Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Astrazeneca Pharma India Ltd
Historical EBITDA of Astrazeneca Pharma India Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Astrazeneca Pharma India Ltd
Historical Net Profit of Astrazeneca Pharma India Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Astrazeneca Pharma India Ltd
Historical Dividend Payouts of Astrazeneca Pharma India Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payouts of Astrazeneca Pharma India Ltd
About Astrazeneca Pharma India Ltd
- AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
- The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
- The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
- Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.
Astrazeneca Pharma India Ltd News Hub
AstraZeneca Pharma fixes record date for final dividend
AstraZeneca Pharma India has fixed 18 July 2025 as record date for final dividend for FY 2024-25. Th
Read more
12 Jul 25
AstraZeneca Pharma to launch Eculizumab (Soliris) in India
AstraZeneca Pharma India announced that it will launch Eculizumab (Soliris) in August 2025 in India
Read more
06 Aug 25
Astrazeneca Pharma India standalone net profit rises 47.54% in the March 2025 quarter
Net profit of Astrazeneca Pharma India rose 47.54% to Rs 58.25 crore in the quarter ended March 2025
Read more
31 May 25
Volumes soar at Astrazeneca Pharma India Ltd counter
Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas Ltd are am
Read more
02 Jun 25